R. V. Larocca

984 total citations
19 papers, 813 citations indexed

About

R. V. Larocca is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, R. V. Larocca has authored 19 papers receiving a total of 813 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 6 papers in Genetics. Recurrent topics in R. V. Larocca's work include Glioma Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Treatment and Pharmacology (5 papers). R. V. Larocca is often cited by papers focused on Glioma Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Treatment and Pharmacology (5 papers). R. V. Larocca collaborates with scholars based in United States, Malaysia and Hungary. R. V. Larocca's co-authors include C.A. Stein, Nanette McAtee, Rose V. Thomas, Charles E. Myers, P L Choyke, Nancy A. Dawson, McClellan M. Walther, Geoffrey R. Weiss, Michael R. Cooper and Margaret Uhrich and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and JNCI Journal of the National Cancer Institute.

In The Last Decade

R. V. Larocca

19 papers receiving 788 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. V. Larocca United States 9 295 230 227 204 171 19 813
Fernando Pardal Portugal 16 404 1.4× 211 0.9× 123 0.5× 236 1.2× 70 0.4× 26 829
A M Schwartz United States 12 486 1.6× 129 0.6× 113 0.5× 277 1.4× 90 0.5× 21 947
Yvonne T.M. Tsang United States 18 533 1.8× 211 0.9× 141 0.6× 329 1.6× 93 0.5× 24 1.2k
Laurence Maggiorella France 11 340 1.2× 153 0.7× 115 0.5× 291 1.4× 46 0.3× 17 793
Seong Hoe Park South Korea 22 373 1.3× 90 0.4× 113 0.5× 350 1.7× 211 1.2× 62 1.4k
Roger Mouawad France 21 523 1.8× 177 0.8× 155 0.7× 308 1.5× 121 0.7× 57 968
Johanna Tapper Finland 14 701 2.4× 353 1.5× 229 1.0× 339 1.7× 158 0.9× 22 1.4k
Junliang Lu China 18 334 1.1× 253 1.1× 185 0.8× 435 2.1× 162 0.9× 48 961
Miki Hashimura Japan 23 731 2.5× 255 1.1× 132 0.6× 396 1.9× 151 0.9× 56 1.4k
Sung‐Im Do South Korea 16 399 1.4× 258 1.1× 175 0.8× 340 1.7× 145 0.8× 84 913

Countries citing papers authored by R. V. Larocca

Since Specialization
Citations

This map shows the geographic impact of R. V. Larocca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. V. Larocca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. V. Larocca more than expected).

Fields of papers citing papers by R. V. Larocca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. V. Larocca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. V. Larocca. The network helps show where R. V. Larocca may publish in the future.

Co-authorship network of co-authors of R. V. Larocca

This figure shows the co-authorship network connecting the top 25 collaborators of R. V. Larocca. A scholar is included among the top collaborators of R. V. Larocca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. V. Larocca. R. V. Larocca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Mantica, Guglielmo, Nazareno Suardi, Francesco Esperto, et al.. (2021). Are urologists ready for interpretation of multiparametric MRI findings? A prospective multicentric evaluation. European Urology. 79. S1281–S1281. 1 indexed citations
2.
Zheng, Baowen, Huaitao Yang, Chengquan Zhao, et al.. (2017). Dermatopathology. Laboratory Investigation. 97(S1). 126–138. 2 indexed citations
3.
Reardon, David A., Surasak Phuphanich, Robert Aiken, et al.. (2014). AT-60 * A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) VACCINE ICT-107 FOLLOWING STANDARD TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH GBM. Neuro-Oncology. 16(suppl 5). v22–v22. 19 indexed citations
4.
Vassilopoulou‐Sellin, Rena, Antonio Tito Fojo, William Oh, et al.. (2007). A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Journal of Clinical Oncology. 25(18_suppl). 15527–15527. 42 indexed citations
5.
Bradford, Daniel S., Mark A. Socinski, R. V. Larocca, Thomas A. Hensing, & Rodolfo Bordoni. (2007). Phase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 18005–18005. 5 indexed citations
6.
Belani, Chandra P., John Barstis, R. V. Larocca, et al.. (2005). O-093 Meta-analysis of weekly paclitaxel as maintenance therapy foradvanced non-small cell lung cancer (NSCLC) patients following intitial chemotherapy. Lung Cancer. 49. S33–S33. 2 indexed citations
7.
Laber, Damian A., Vivek R. Sharma, R. V. Larocca, et al.. (2005). Phase II study of cyclophosphamide, etoposide and estramustine in patients with androgen independent prostate cancer. Journal of Clinical Oncology. 23(16_suppl). 4757–4757. 1 indexed citations
8.
9.
Ramalingam, S., Michael C. Perry, R. V. Larocca, et al.. (2005). Outcome of elderly (≥70 years) non-small cell lung cancer (NSCLC) patients on a multicenter, phase III randomized trial comparing weekly vs. standard schedules of paclitaxel (P) plus carboplatin (C). Journal of Clinical Oncology. 23(16_suppl). 7149–7149. 4 indexed citations
10.
11.
Larocca, R. V., et al.. (2004). High-dose (HD) irinotecan in patients with recurrent unresectable high-grade gliomas on glucoronidation-enhancing anticonvulsants (GEACs): A phase I/II study. Journal of Clinical Oncology. 22(14_suppl). 1578–1578. 2 indexed citations
12.
Kamar, F. G., Lisa M. DeAngelis, J Yahalom, et al.. (2004). Combined immunochemotherapy with reduced dose whole brain radiotherapy (WBRT) for newly diagnosed patients with primary CNS lymphoma (PCNSL). Journal of Clinical Oncology. 22(14_suppl). 1518–1518. 2 indexed citations
13.
Belani, Chandra P., R. V. Larocca, David Rinaldi, et al.. (2004). A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel. Journal of Clinical Oncology. 22(14_suppl). 7017–7017. 14 indexed citations
14.
15.
Myers, Christopher D., Michael R. Cooper, C.A. Stein, et al.. (1992). Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.. Journal of Clinical Oncology. 10(6). 881–889. 200 indexed citations
16.
Yano, Tomohiro, M. Linehan, Michael I. Lerman, et al.. (1989). Genetic Changes in Human Adrenocortical Carcinomas. JNCI Journal of the National Cancer Institute. 81(7). 518–519. 96 indexed citations
17.
Stein, C.A., R. V. Larocca, Rose V. Thomas, Nanette McAtee, & Charles E. Myers. (1989). Suramin: an anticancer drug with a unique mechanism of action.. Journal of Clinical Oncology. 7(4). 499–508. 320 indexed citations
18.
Larocca, R. V., Mark L. Rosenblum, Bengt Westermark, & Mark A. Israel. (1989). Patterns of proto‐oncogene expression in human glioma cell lines. Journal of Neuroscience Research. 24(1). 97–106. 34 indexed citations
19.
Feuillan, Penelope, Mark Raffeld, C.A. Stein, et al.. (1987). Effects of Suramin on the Function and Structure of the Adrenal Cortex in the Cynomolgus Monkey. The Journal of Clinical Endocrinology & Metabolism. 65(1). 153–158. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fernando Pardal Breakdown of academic impact, for papers by A M Schwartz Breakdown of academic impact, for papers by Yvonne T.M. Tsang Breakdown of academic impact, for papers by Laurence Maggiorella Breakdown of academic impact, for papers by Seong Hoe Park Breakdown of academic impact, for papers by Roger Mouawad Breakdown of academic impact, for papers by Johanna Tapper Breakdown of academic impact, for papers by Junliang Lu Breakdown of academic impact, for papers by Miki Hashimura Breakdown of academic impact, for papers by Sung‐Im Do
Rankless by CCL
2026